Batavia Biosciences teams up with international consortium to support polio eradicationTuesday, January 16, 2018
With a 99% reduction in polio cases worldwide since 1988, the global eradication of polio is now in sight. In support of the polio eradication initiative, novel oral polio vaccine (nOPV) candidates are being developed that are intended to reduce the risk from rare cases of vaccine-associated disease. The novel strains are intended to be stockpiled as protection against possible future outbreaks after polio has been eradicated.
The novel candidate vaccine strains currently in manufacturing at Batavia Biosciences have been developed by the National Institute for Biological Standards and Control (NIBSC) in the United Kingdom, the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and the University of California at San Francisco (UCSF). Batavia Biosciences contributes its extensive polio vaccine development experience and works closely with one of the world’s leading OPV vaccine manufacturers, Bio Farma, in Indonesia, under the nOPV consortium managed by PATH.
Chris Yallop, CSO of Batavia Biosciences, states: “With such a consortium, I am convinced that we will succeed in taking the next step in the development of this much needed vaccine.”
Menzo Havenga, CEO of Batavia Biosciences, states: “We are proud to work with the Bill & Melinda Gates Foundation, PATH, NIBSC and Bio Farma, and on the goal of bringing a safer oral polio vaccine to help keep the world polio-free.”
Dutch Visitors Programme to the BIO 2018
New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease
Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy